The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the ...
Alexion already has a newer product to defend the franchise in Ultomiris (ravulizumab), a longer-acting C5 inhibitor that requires dosing every eight weeks while Soliris is given every two weeks.
NICE and Alexion not backing down The Soliris appraisal has largely been conducted via complex health economic arguments and counter arguments, but NICE's HST committee and representatives came ...
Amgen has developed biosimilars of J&J’s Stelara (Wezlana/ABP 654), Alexion’s Soliris (Bekemv/ABP 959) and Regeneron’s Eylea (ABP 938). Wezlana was approved in 2023 and launched in January 2025.
Zacks Investment Research on MSN2d
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...
All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.
Generalised myasthenia gravis (gMG) is a chronic disorder in which the body's immune system mistakenly targets the neuromuscular junctions—areas where nerves signal muscles to move. This ...
EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases. With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback